Last 0.50 GBp
Change Today +0.025 / 5.26%
Volume 1.2M
SAR On Other Exchanges
Symbol
Exchange
London
As of 11:30 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

sareum holdings plc (SAR) Snapshot

Open
0.48 GBp
Previous Close
0.48 GBp
Day High
0.50 GBp
Day Low
0.48 GBp
52 Week High
09/24/13 - 1.13 GBp
52 Week Low
05/9/14 - 0.38 GBp
Market Cap
9.6M
Average Volume 10 Days
3.4M
EPS TTM
--
Shares Outstanding
1.9B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAREUM HOLDINGS PLC (SAR)

Related News

No related news articles were found.

sareum holdings plc (SAR) Related Businessweek News

No Related Businessweek News Found

sareum holdings plc (SAR) Details

Sareum Holdings plc, through its subsidiaries, is engaged in the discovery and development of therapeutic drugs for the treatment of cancer and auto-immune diseases. The company focuses on developing small molecule drug candidates for licensing to pharmaceutical and biotechnology companies. Its principal drug discovery programs include Checkpoint kinase 1 (Chk1), Aurora+Fms-like Tyrosine Kinase 3 (FLT3), Tyrosine kinase 2 (TYK2), Vascular Endothelial Growth Factor Receptor 3 Kinase (VEGFR-3), and Fatty Acid Synthase (FASN); and other programs, such as Anaplastic Lymphoma Kinase (ALK), FLT3, microtubule binding agents, Polo-like Kinase (PLK), and B-raf for various cancer indications. Sareum Holdings plc has collaborations with The Institute of Cancer Research and Cancer Research Technology Limited for developing Chk1 kinase; SRI international for developing TYK2 kinase; and Technology Strategy Board for developing FASN. The company was founded in 2003 and is headquartered in Cambridge, the United Kingdom.

2 Employees
Last Reported Date: 11/13/13
Founded in 2003

sareum holdings plc (SAR) Top Compensated Officers

Founder, Chief Executive Officer, Director an...
Total Annual Compensation: 88.0K GBP
Founder, Chief Scientific Officer and Directo...
Total Annual Compensation: 88.0K GBP
Compensation as of Fiscal Year 2013.

sareum holdings plc (SAR) Key Developments

Sareum Announces Japanese Patent Grant for Kinase Inhibitors

Sareum announced that the company has been notified by the Japan Patent Office that a patent has been granted for one of Sareum's key drug discovery inventions. This patent, which relates to compounds that inhibit or modulate the activity of kinase enzymes, forms the basis of Sareum's SKIL® drug discovery platform. The granting of this patent means that Sareum has approved patent protection in the Japan for its SKIL platform and many of its drug discovery programmes. The Company expects to receive similar protection in Europe and other major markets in due course. SKIL (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the company's Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc Announces Co-Development Agreement Co-Development Agreement with Hebei Medical University Biomedical Engineering Center for Aurora+FLT3

Sareum Holdings plc announced that it has signed a co-development agreement with Hebei Medical University Biomedical Engineering Center to advance its Aurora+FLT3 cancer programme. Under the terms of the agreement HMUBEC has been granted exclusive rights to carry out pre-clinical and clinical studies within Greater China to obtain approval for sales in that territory. Sareum will receive a significant milestone payment once a product receives authorization for marketing, and up to 15% of operating profit from sales generated in Greater China. HMUBEC will be required to disclose and exclusively license to Sareum all pre-clinical and clinical data it generates in the course of the development collaboration in order to facilitate Sareum's own development and commercialization activities. This would include conducting any further studies required for authorization for clinical trials in the rest of the world as well as out-licensing and supporting applications for marketing authorizations outside Greater China. HMUBEC will be entitled to receive up to 10% of operating profit Sareum receives from any license agreement or sales made outside Greater China, dependent on the stage at which Sareum out-licences data generated by HMUBEC to a third party.

Sareum Holdings plc, Annual General Meeting, Dec 11, 2013

Sareum Holdings plc, Annual General Meeting, Dec 11, 2013., at 10:00 GMT Standard Time. Location: offices of Hybridan LLP, Warnford Court.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAR:LN 0.50 GBp +0.025

SAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SAR.
View Industry Companies
 

Industry Analysis

SAR

Industry Average

Valuation SAR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREUM HOLDINGS PLC, please visit www.sareum.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.